Research programme: hydroxysteroid dehydrogenase inhibitors - AbbVie

Drug Profile

Research programme: hydroxysteroid dehydrogenase inhibitors - AbbVie

Alternative Names: Metabolic syndrome therapy - Abbott

Latest Information Update: 08 Feb 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Amidines
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Metabolic syndrome

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 29 Mar 2012 Early research is ongoing in USA
  • 16 Apr 2007 Early research in Metabolic syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top